Clinical Trial Update: Karyopharm Expanded Access Program for Selinexor

View source ↗

Summary

This update covers Karyopharm's Expanded Access Program for selinexor (Xpovio), including eligibility and current availability for listed cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Endometrial Cancer
• Glioblastoma
• Multiple Myeloma
• Myelofibrosis
• Peripheral T-cell Lymphoma
• Sarcoma

Drugs mentioned

• XPOVIO (selinexor) (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL) | Status: AVAILABLE